34 Supported by research
Cardiovascular disease is the leading cause of death worldwide and is the leading cause of death among women.
"Yeah, it's still the number one killer around the world, not just here. And it's still the number one killer in women who, you know, they think that it's breast cancer. No, no, this is it." (said at 0:00:03)
Global epidemiological surveillance consistently establishes that cardiovascular disease (CVD) is the leading cause of death globally and specifically the leading cause of mortality among women. According to data from the Global Burden of Disease (GBD) studies, CVD accounted for over 19 million deaths worldwide in 2023, with ischemic heart disease and stroke as the predominant causes. The Lancet Commission on Women and Cardiovascular Disease similarly confirms that CVD is the leading cause of death in women globally, causing far more female deaths than breast cancer or other malignancies.
Approximately 80% of heart disease and diabetes cases are preventable with diet and lifestyle modifications.
"But we know that 80% of cases of heart disease and diabetes may actually be preventable with diet and lifestyle." (said at 0:00:31)
Large prospective cohort analyses indicate that approximately 80% or more of coronary heart disease and type 2 diabetes cases are attributable to modifiable lifestyle factors, including diet quality, physical activity, body mass index, and non-smoking status. In landmark analyses from the Nurses' Health Study, 82% of coronary events and 91% of type 2 diabetes cases were attributable to non-adherence to a low-risk diet and lifestyle pattern.
Fewer than 3% of the United States population meets four core low-risk lifestyle characteristics: non-smoking, 150 minutes of weekly exercise, diet in the top two quintiles of whole foods, and a healthy body fat percentage.
"fewer than 3% of the US population is meeting the core four basic characteristics that predict low risk. And it's a pretty low bar, Mark... It's not smoking... Getting the minimum recommended 150 minutes of exercise a week, eating in the top two quintiles of what's considered a whole foods diet, and having a healthy body fat percentage. Fewer than 3%." (said at 0:02:45)
A nationally representative study of US adults using 2003–2006 National Health and Nutrition Examination Survey (NHANES) data evaluated four healthy lifestyle characteristics: being sufficiently physically active (measured via accelerometry), eating a healthy diet (top 40% of the Healthy Eating Index), being a non-smoker (serum cotinine), and having a recommended body fat percentage (measured via DXA). The authors found that only 2.7% (95% CI, 1.9%–3.4%) of US adults met all four criteria, directly supporting the claim.
Standard clinical lipid panels calculate LDL cholesterol via a mathematical formula rather than directly measuring it.
"and they would do a standard cholesterol profile, which interestingly enough calculates your LDL cholesterol, the one we usually think of as being the lousy cholesterol, from a formula, doesn't even really measure it" (said at 0:05:42)
Standard clinical lipid panels typically measure total cholesterol, HDL cholesterol, and triglycerides directly, while calculating LDL cholesterol using mathematical formulas (most commonly the Friedewald equation, or newer alternatives such as Martin-Hopkins or Sampson equations) rather than direct homogeneous assays or reference ultracentrifugation.
Large pattern A LDL particles are less prone to oxidative stress, inflammation, and plaque rupture compared to small, dense pattern B LDL particles.
"There's big, fluffy, puffy pattern A LDL cholesterol, which is less easily made into a plaque in the artery, less prone to inflammation and oxidative stress and rupture. So it's a less risky LDL, whereas somebody could have small, dense pattern B LDL, and that's the really risky LDL." (said at 0:09:21)
Published experimental and observational studies demonstrate that large, buoyant LDL particles (predominant in LDL phenotype pattern A) are more resistant to oxidative modification and less strongly associated with pro-inflammatory vascular activation and atherosclerotic progression than small, dense LDL particles (pattern B). Biochemical assays show that resistance to oxidation (measured by lag time before copper-induced oxidation) is significantly longer in larger LDL fractions and shorter in dense fractions, making small dense LDL more susceptible to oxidative modification. Additionally, pattern B profiles are associated with elevated expression of pro-inflammatory cytokines and chemokines and increased cardiovascular risk.
According to NHANES data from 2009 to 2016, only 12.2% of American adults were metabolically healthy across key markers including blood pressure, HDL, triglycerides, and fasting glucose.
"So, a recent study was looking at the NHANES data from 2009 to 2016, government surveys... And they found that 12.2% of Americans... 12.2% of Americans were metabolically healthy" (said at 0:16:29)
A widely cited analysis of NHANES data from 2009 to 2016 (n = 8,721 adults) by Araújo et al. (2019) evaluated metabolic health defined by optimal levels of five cardiometabolic risk factors (waist circumference, blood pressure, fasting glucose/HbA1c, triglycerides, and HDL cholesterol without medication). Using the most recent clinical guidelines, only 12.2% (95% CI: 10.9–13.6%) of American adults met the criteria for optimal metabolic health.
- supports: Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition E… (Metabolic syndrome and related disorders 2019) · cited 157x in the literature
"Data from the National Health and Nutrition Examination Survey 2009-2016 were analyzed (n = 8721). Using the most recent guidelines, metabolic health was defined as having optimal levels of waist circumference (WC <102/88 cm for men/women), glucose (fasting glucose <100 mg/dL and hemoglobin A1c <5.7%), blood pressure (systolic <120 and diastolic <80 mmHg), triglycerides (<150 mg/dL), and high-density lipoprotein cholesterol (≥40/50 mg/dL for men/women), and not taking any related medication. Changing from ATP III (Adult Treatment Panel III) guidelines to more recent cut points decreased the proportion of metabolically healthy Americans from 19.9% (95% confidence interval [CI]: 18.3-21.5) to 12.2% (95% CI: 10.9-13.6)." (abstract, results, passage verified)
pubmedfull study (doi)
Fewer than one-third of normal-weight individuals in the US are metabolically healthy.
"Fewer than one-third of so-called normal-weight people were metabolically healthy. So, that's another really important message." (said at 0:17:21)
A nationally representative study of US adults using National Health and Nutrition Examination Survey (NHANES) 2009–2016 data (n = 8,721) evaluated optimal cardiometabolic health based on guidelines for waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol without medication. The study found that less than one-third of normal-weight adults met criteria for optimal metabolic health.
Ninety percent of Americans with prediabetes are undiagnosed by their physicians.
"when you look at that data and you also look at the parallel data that 90% of Americans with pre-diabetes are not diagnosed by their doctor, right?" (said at 0:19:00)
Surveillance data from the Centers for Disease Control and Prevention (CDC) using the National Health and Nutrition Examination Survey (NHANES) consistently demonstrate that approximately 85% to 90% of US adults meeting clinical criteria for prediabetes are unaware of their condition and have not been told by a health professional that they have it. In NHANES analyses, only 11% to 16% of adults with laboratory-defined prediabetes reported being aware of their diagnosis.
- supports: Awareness of prediabetes--United States, 2005-2010. (MMWR. Morbidity and mortality weekly report 2013) · cited 65x in the literature
"This report describes the results of that analysis, which indicated that, during 2009-2010, approximately 11% of those with prediabetes were aware of their condition. Furthermore, during 2005-2010, estimated awareness of prediabetes was <14% across all population subgroups, different levels of health-care access or use, and other factors." (abstract, results, passage verified)
pubmed - supports: Prediabetes awareness is not associated with lower consumption of self-reported added suga… (Annals of epidemiology 2022) · cited 2x in the literature
"Among 3314 adults with prediabetes, 528 reported being aware and 2786 reported being unaware of their condition." (abstract, results, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist drugs reduce systemic inflammation independently of and prior to weight loss.
"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese." (said at 0:26:30)
Randomized clinical trials and translational research demonstrate that GLP-1 receptor agonists exert direct anti-inflammatory effects that occur acutely (even following a single dose) and independently of weight reduction. In human trials, GLP-1 receptor agonism rapidly downregulates reactive oxygen species generation, NF-κB binding, and proinflammatory cytokine expression (including TNF-α, IL-1β, and IL-6) as well as systemic markers such as high-sensitivity C-reactive protein before or in the absence of significant weight loss.
- supports: Exenatide exerts a potent antiinflammatory effect. (The Journal of clinical endocrinology and metabolism 2012) · cited 286x in the literature
"After a single injection of exenatide, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive oxygen species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression... Exenatide exerts a rapid antiinflammatory effect at the cellular and molecular level. This may contribute to a potentially beneficial antiatherogenic effect. This effect was independent of weight loss." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benef… (The Journal of clinical investigation 2025) · cited 74x in the literature
"Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines." (abstract, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist medications prevent or improve heart failure with preserved ejection fraction (HFpEF).
"And we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:26:40)
Large phase 3 randomized controlled trials have demonstrated that the GLP-1 receptor agonist semaglutide substantially improves symptoms, physical functioning, and clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF and STEP-HFpEF DM trials, once-weekly semaglutide significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) scores and 6-minute walk distance while reducing body weight compared with placebo in patients with obesity-related HFpEF. Furthermore, a pooled analysis of 3,743 participants across four randomized trials (STEP-HFpEF, STEP-HFpEF DM, SELECT, and FLOW) showed that semaglutide significantly reduced the risk of worsening heart failure events (HR 0.59, 95% CI 0.41–0.82) and composite cardiovascular death or heart failure events (HR 0.69, 95% CI 0.53–0.89).
AI analysis of retinal images can predict coronary artery calcium scores, stroke risk, and heart disease.
"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell if you're going to, um, you know, your calcium score of your heart arteries through your retina." (said at 0:27:40)
Published studies confirm that artificial intelligence and deep-learning models applied to retinal fundus photographs can predict coronary artery calcium (CAC) scores, incident cardiovascular disease, and stroke risk. Deep-learning algorithms have demonstrated discrimination of high CAC scores (>100) from zero CAC with an AUROC of approximately 0.83. Furthermore, systematic reviews and cohort studies show that retinal microvascular biomarkers and AI retinal models predict future cardiovascular events (such as myocardial infarction, cardiovascular mortality, and stroke) with predictive accuracy comparable to conventional clinical risk scores.
Pericoronary arterial inflammation detected by AI analysis on CT angiography in the absence of arterial narrowing is associated with up to a 15-fold increased risk of heart attack.
"No, no, the Cleerly and the other ones in the US don't do this, but this is a a a Oxford, University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrow, it's, you know, you could have 15-fold risk of a heart attack." (said at 0:28:49)
The claim is supported by large prospective cohort data from University of Oxford researchers and the associated spinout technology (Caristo's AI-assisted perivascular Fat Attenuation Index [FAI] Score). In the ORFAN multicentre longitudinal cohort study published in The Lancet (2024), coronary inflammation measured by FAI Score on coronary CT angiography was evaluated in patients with and without obstructive coronary artery disease. Having high perivascular inflammation across coronary arteries was associated with a 12.6-fold increased risk of major adverse cardiac events (MACE, including myocardial infarction; HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold increased risk of cardiac mortality, independent of anatomical stenosis.
Adhering to comprehensive healthy lifestyle practices provides 7 to 10 additional years of life free from major age-related chronic diseases.
"show that if we practice the lifestyle factors that we've been reviewing with the details, um, that we we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:29:50)
A prospective analysis of 111,562 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study investigated the impact of five low-risk lifestyle factors (a healthy diet, never smoking, ≥30 minutes/day of moderate-to-vigorous physical activity, moderate alcohol consumption, and a normal BMI). At age 50, women adhering to four or five healthy lifestyle factors had 34.4 years of life expectancy free of diabetes, cardiovascular disease, and cancer compared to 23.7 years for those with zero factors (a gain of 10.7 disease-free years). For men, the disease-free life expectancy at age 50 was 31.1 years versus 23.5 years (a gain of 7.6 disease-free years), directly supporting the claim of 7 to 10 additional years of life free from major chronic diseases.
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.
"preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:26:26)
Large population-based epidemiological studies establish that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (roughly 45% to 55%) of all heart failure cases in clinical practice and community cohorts.
Approximately 50% of American adults have either prediabetes or type 2 diabetes.
"I mean, okay, one out of two Americans has pre-diabetes or type 2 diabetes." (said at 0:17:59)
Nationally representative surveillance data from the National Health and Nutrition Examination Survey (NHANES) support the claim that approximately 50% (one out of two) of American adults have either diabetes or prediabetes. In a landmark NHANES analysis, the unadjusted prevalence among US adults was 14.3% for total diabetes and 38.0% for prediabetes, combining to 52.3%. More recent NHANES analyses (2021–2023) show an age-adjusted diabetes prevalence of 16.3% and prediabetes prevalence of 30.7%, combining to 47.0%.
- supports: Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. (JAMA 2015) · cited 2411x in the literature
"In the overall 2011-2012 population, the unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and prediabetes) was 14.3% (95% CI, 12.2%-16.8%) for total diabetes, 9.1% (95% CI, 7.8%-10.6%) for diagnosed diabetes, 5.2% (95% CI, 4.0%-6.9%) for undiagnosed diabetes, and 38.0% (95% CI, 34.7%-41.3%) for prediabetes" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Am… (Diabetes, obesity & metabolism 2026)
"The age-adjusted prevalence of total diabetes was stable across the study period: 14.6% (95% CI 13.0%-16.2%) in 2013-2014 and 16.3% (14.6%-18.0%) in 2021-2023... The age-adjusted prevalence of pre-diabetes increased significantly during the study period from 26.4% (23.7%-29.1%) in 2013-2014 to 30.7% (28.4%-33.0%) in 2021-2023" (abstract, results)
pubmedfull study (doi)
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein.
"drugs that lower this genetically determined lipoprotein called Lp(a)" (said at 0:30:23)
Lipoprotein(a), or Lp(a), is well-established in the scientific literature as a predominantly genetically determined lipoprotein. Circulating Lp(a) concentrations are largely controlled by variations at the LPA gene locus (including kringle IV type-2 copy number variation and specific single-nucleotide variants), demonstrating an estimated 70% to 90% heritability and remaining largely unaffected by diet and routine lifestyle modifications.
Clinical trial data demonstrate that the lower LDL cholesterol is reduced, the greater the cardiovascular protection.
"Well, if you look at all the data, the lower you go, the more protection" (said at 0:31:12)
Large meta-analyses of randomized controlled trials (such as the Cholesterol Treatment Trialists' Collaboration) and individual trial analyses (such as FOURIER and FOURIER-OLE) demonstrate a consistent, log-linear relationship where lower achieved low-density lipoprotein cholesterol (LDL-C) levels yield progressively greater reductions in major cardiovascular events, without a discernible lower threshold for clinical efficacy down to very low LDL-C levels (<20 mg/dL).
- supports: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data… (Lancet (London, England) 2010) · cited 6539x in the literature
"Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth. There was no evidence of any threshold within the cholesterol range studied, suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50%." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Card… (Circulation 2023) · cited 185x in the literature
"There was a monotonic relationship between lower achieved LDL-C levels-down to very low levels <20 mg/dL-and a lower risk of the primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) and the key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) that persisted after multivariable adjustment (adjusted P trend <0.0001 for each end points)." (abstract, results, passage verified)
pubmedfull study (doi)
Clinical data do not show that statins cause cognitive impairment or sexual dysfunction.
"Now, with respect to cognitive and, uh, sexual dysfunction, the data really don't show a hit there at all" (said at 0:32:45)
High-certainty evidence from randomized controlled trials and meta-analyses supports the claim that clinical data do not demonstrate a causal link between statin therapy and cognitive impairment or sexual dysfunction. A meta-analysis of individual participant data from 19 double-blind randomized trials encompassing 123,940 individuals found no evidence that statins cause cognitive impairment or other non-hepatic/non-muscular undesirable effects listed in product labels. Furthermore, systematic reviews and meta-analyses of randomized controlled trials evaluating lipid-lowering therapies (including statins) have found no significant association with neurocognitive disorders or global cognitive decline compared to placebo or control groups.
Alzheimer's disease accounts for 70% of dementia cases.
"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 0:32:54)
Epidemiological consensus establishes that Alzheimer's disease is the leading cause of dementia, accounting for an estimated 60% to 70% of all dementia cases globally.
High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes.
"because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right? ... high doses of rosuvastatin, Crestor, or atorvastatin, Lipitor, that could also raise the risk of that person developing type 2 diabetes." (said at 0:34:00)
Large meta-analyses of randomized controlled trials demonstrate that statin therapy—and particularly intensive-dose or high-potency statin regimens such as high-dose atorvastatin and rosuvastatin—is associated with a modest, statistically significant increase in the risk of developing new-onset type 2 diabetes. A 2011 meta-analysis of 5 randomized trials (32,752 participants) comparing intensive-dose to moderate-dose statin therapy found a 12% increased odds of incident diabetes (OR 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years. This dose-dependent diabetogenic effect is well recognized, although guidelines emphasize that cardiovascular benefits generally outweigh this risk in indicated patients.
- supports: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin … (Lancet (London, England) 2010) · cited 2464x in the literature
"Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011) · cited 1395x in the literature
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... Odds ratios were 1.12 (95% confidence interval [CI], 1.04-1.22; I(2) = 0%) for new-onset diabetes... In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Muscle biopsies of individuals taking statins show mitochondrial damage even in the absence of muscle pain or elevated muscle enzymes.
"some of the data I've seen that even in people without muscle pain, even without elevated muscle enzymes, that there's mitochondrial damage on muscle biopsies." (said at 0:35:20)
Published clinical studies evaluating skeletal muscle biopsies (e.g., vastus lateralis) from statin users have demonstrated subclinical perturbations in mitochondrial function and content—including decreased citrate synthase activity, repressed expression of mitochondrial gene pathways, and altered oxidative capacity—even in patients who are asymptomatic (without myalgias) and have normal serum creatine kinase levels.
- supports: Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after init… (Translational research : the journal of laboratory and clinical medicine 2015) · cited 6x in the literature
"As expected, simvastatin lowered low-density lipoprotein, but did not induce myalgias or significant increases in serum creatine kinase. However, we found subtle but significant reductions in muscle citrate synthase activity and REE. In addition, quantitative polymerase chain reaction and gene set enrichment analysis of muscle samples revealed significantly repressed gene sets involved in mitochondrial function and induced gene sets involved in remodeling of the extracellular matrix." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism… (The Journal of clinical endocrinology and metabolism 2018) · cited 57x in the literature
"Mitochondrial content tended to be lower in both statin groups than in control subjects. Statin use attenuated substrate use during maximal exercise performance, induced muscle fatigue during repeated muscle contractions, and decreased muscle mitochondrial oxidative capacity. This suggests disturbances in mitochondrial oxidative capacity occur with statin use even in patients without statin-induced muscle complaints." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
PCSK9 inhibitor injectable medications are not associated with an increased risk of diabetes.
"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes" (said at 0:35:53)
Extensive randomized controlled trial evidence and systematic reviews demonstrate that injectable PCSK9 monoclonal antibodies (such as evolocumab and alirocumab) do not increase the risk of new-onset diabetes or impair glycemic parameters (fasting plasma glucose, HbA1c), unlike statin therapy. A 2022 systematic review and meta-analysis of 32 trials comprising 65,861 participants evaluated this outcome with high certainty evidence and confirmed no increased risk of new-onset diabetes.
- supports: Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on n… (Diabetes, obesity & metabolism 2018) · cited 57x in the literature
"Alirocumab and evolocumab, two types of PCSK9-mAb approved by the US Food and Drug Administration and the European Medicines Agency, had no significant impact on NODM and glucose homeostasis, regardless of PCSK9-mAb type, participant characteristics, treatment duration, treatment method and differences in control treatment." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onse… (Journal of cardiovascular pharmacology and therapeutics 2020) · cited 25x in the literature
"Participants randomized to PCSK9i did not differ from the control patients in diabetes incidence (risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and met… (Heart (British Cardiac Society) 2022) · cited 29x in the literature
"PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus, neurocognitive events, cataracts or gastrointestinal haemorrhage with high certainty evidence." (abstract, results, passage verified)
pubmedfull study (doi)
Saturated fat consumption raises LDL cholesterol.
"and we know saturated fat raises LDL cholesterol" (said at 0:44:24)
Extensive randomized controlled trial evidence and systematic reviews consistently show that consumption of saturated fatty acids increases circulating LDL cholesterol (and conversely, reducing dietary saturated fat or replacing it with unsaturated fats lowers total and LDL cholesterol).
- supports: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"There was little or no effect on cancer mortality, cancer diagnoses, diabetes diagnosis, HDL cholesterol, serum triglycerides or blood pressure, and small reductions in weight, serum total cholesterol, LDL cholesterol and BMI." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of Replacement of Individual Dietary SFAs on Circulating Lipids and Other Biomarker… (Advances in nutrition (Bethesda, Md.) 2022) · cited 38x in the literature
"We observed reductions in LDL-cholesterol concentrations after the replacement of palmitic acid (16:0) with UFAs (-0.36 mmol/L; 95% CI: -0.50, -0.21 mmol/L; I2 = 96.0%, n = 18 RCTs) or oleic acid (18:1n-9) (-0.16 mmol/L; 95% CI: -0.28, -0.03 mmol/L; I2 = 89.6%, n = 9 RCTs), with a similar impact on total cholesterol and apoB concentrations." (abstract, results, passage verified)
pubmedfull study (doi)
Statins exhibit distinct anti-inflammatory and anti-clotting mechanisms independent of cholesterol lowering.
"statins had a separate effect to lower cholesterol, which is their anti-inflammatory and their anti-clotting." (said at 0:44:33)
The claim is supported. Extensive clinical and mechanistic literature confirms that HMG-CoA reductase inhibitors (statins) exert well-established 'pleiotropic' effects independent of their primary low-density lipoprotein (LDL) cholesterol-lowering pathway. By inhibiting the mevalonate pathway and the isoprenylation of small GTP-binding proteins (such as Rho, Ras, and Rac), statins mediate distinct anti-inflammatory effects (e.g., reductions in hs-CRP, proinflammatory cytokines, and leukocyte adhesion) and antithrombotic/anti-clotting effects (e.g., attenuation of tissue factor expression, inhibition of platelet activation and thrombus formation, and modulation of fibrin clot properties).
A systematic review of over 30 randomized controlled trials found no clear relationship between the degree of LDL reduction from cholesterol-lowering drugs and prevention of cardiovascular events.
"So myself and two cardiologists did a systematic review of the totality of drug industry-sponsored trials, by the way, and some diet trials, but many drug industry-sponsored trials, all of the randomized controlled trials on cholesterol-lowering drugs: statins, PCSK9, blah, blah. Was there a clear relationship as you lowered LDL in low-risk and high-risk patients, Mark, okay, over 30 studies, was there a relationship with lowering LDL and preventing cardiovascular events? No." (said at 0:48:30)
The speaker accurately describes the findings of a published systematic review of 35 randomized controlled trials (PMID 32747335), which he co-authored. The review analyzed trials evaluating LDL cholesterol targets across diverse risk populations and concluded that achieving specific LDL target levels through drug therapy did not confer consistent cardiovascular benefit, questioning the direct relationship between LDL-C lowering as a surrogate target and cardiovascular event reduction. A subsequent 2022 systematic review and meta-regression in JAMA Internal Medicine (PMID 35285850) evaluating statin trials similarly concluded that a conclusive relationship between the magnitude of absolute LDL-C reduction and individual clinical outcomes (all-cause mortality, myocardial infarction, stroke) was not established.
A study of emergency room patients presenting with heart attacks showed that two-thirds had diabetes or pre-diabetes upon glucose tolerance testing.
"where they looked basically at a series of patients who came into an emergency room with a heart attack and they did glucose tolerance tests on everybody who came in with a heart attack and they found that two-thirds either had diabetes or pre-diabetes who had a heart attack." (said at 0:53:25)
The host's claim accurately describes the findings of landmark prospective studies evaluating glucometabolic status in patients with acute myocardial infarction (AMI). In the Glucose Tolerance in Patients with Acute Myocardial Infarction (GAMI) study, 181 consecutive patients admitted with acute MI without previously diagnosed diabetes were evaluated with an oral glucose tolerance test (OGTT). At hospital discharge, 35% had impaired glucose tolerance (pre-diabetes) and 31% had previously undiagnosed diabetes mellitus, totaling 66% (two-thirds) of the cohort. At three months post-discharge, 40% had impaired glucose tolerance and 25% had diabetes, maintaining the overall two-thirds prevalence of dysglycemia.
- supports: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis … (Lancet (London, England) 2002) · cited 1125x in the literature
"58 of 164 (35%, 95% CI 28-43) and 58 of 144 (40%, 32-48) individuals had impaired glucose tolerance at discharge and after 3 months, respectively, and 51 of 164 (31%, 24-38) and 36 of 144 (25%, 18-32) had previously undiagnosed diabetes mellitus." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities … (Diabetes care 2008) · cited 91x in the literature
"At discharge, 34, 31, and 34% were classified as having normal glucose tolerance, impaired glucose tolerance (IGT), or type 2 diabetes, respectively" (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 93% of Americans have obesity, pre-diabetes, or cardiometabolic dysfunction.
"pre-diabetes or metabolic dysfunction, which is basically in America 93% of Americans" (said at 0:54:05)
A nationally representative study of 55,081 U.S. adults using National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2018 evaluated cardiometabolic health across five components: adiposity (BMI and waist circumference), blood glucose, blood lipids, blood pressure, and clinical cardiovascular disease. In 2017–2018, only 6.8% (95% CI: 5.4%–8.1%) of U.S. adults had optimal levels across all five components without medication, meaning approximately 93.2% of American adults had suboptimal cardiometabolic health.
In the Framingham Heart Study, after age 50, mortality increased as total cholesterol dropped.
"another thing that was interesting from Framingham which wasn't well publicized is that when after people hit 50 years old, as their cholesterol dropped, their mortality increased." (said at 0:54:40)
Published analyses of the Framingham Heart Study support the statement. In a 30-year follow-up analysis of Framingham participants published in JAMA (1987), researchers reported that for individuals over age 50, falling total cholesterol levels over a 14-year period were associated with an 11% increase in overall mortality and a 14% increase in cardiovascular mortality for every 1 mg/dL per year decrease in cholesterol. A subsequent 1993 analysis confirmed that total cholesterol was negatively associated with all-cause mortality at age 80 and non-significantly or negatively associated in middle-to-older age groups. The original study authors noted that this observational association in older adults is confounded by reverse causality, wherein developing chronic illnesses cause cholesterol levels to drop prior to death.
A 2016 systematic review of observational cohort studies in people over age 60 found an inverse association between LDL cholesterol and all-cause mortality.
"2016, and the reason we did this, me and a number of international scientists, we decided to do a systematic review of observational data looking at people over 60. ... but what was surprising was there was an inverse association with LDL cholesterol and all-cause mortality. In other words, statistically, if you're over 60, the higher LDL, the less likely you are to die." (said at 0:54:26)
A 2016 systematic review by Ravnskov et al. (published in BMJ Open) evaluated 19 cohort studies comprising 30 cohorts and 68,094 participants aged 60 years and older. The authors reported an inverse association between LDL cholesterol and all-cause mortality in 16 of the 28 cohorts where all-cause mortality was recorded (representing 92% of analyzed participants), with no association found in the remaining cohorts. Because the underlying evidence base consists of observational cohort studies susceptible to reverse causation (e.g., frailty, terminal illness, or malnutrition lowering cholesterol levels prior to death) and residual confounding, the certainty of evidence for this observational association is low.
Low cholesterol levels are associated with an increased incidence of cancer.
"And we also know there is an association—I'll use this word, an association, right? Not definitely causal—between low cholesterol and cancer." (said at 0:55:50)
Epidemiological cohort studies have repeatedly demonstrated an observational association between low serum total cholesterol levels and an increased incidence or mortality of cancer. However, extensive research—including randomized intervention trials, long-term prospective cohorts, and Mendelian randomization analyses—indicates that this relationship is non-causal. Instead, the inverse association is largely explained by reverse causality (subclinical, undiagnosed malignancies consuming or suppressing serum lipids prior to diagnosis) and confounding factors such as underlying liver dysfunction or low albumin levels. Because the speaker explicitly qualified the statement as an observational association rather than a causal link, the statement accurately reflects the epidemiological evidence.
- supports: Low serum cholesterol, cancer and other noncardiovascular disorders. (Atherosclerosis 1992) · cited 30x in the literature
"A review of the evidence from ecological, cross-cultural comparisons, prospective epidemiological cohort studies and intervention trials provides no indication for a cause-and-effect association between low serum cholesterol or serum cholesterol lowering and the risk of cancer, except possibly at very low levels." (abstract, passage verified)
pubmedfull study (doi) - supports: Liver diseases and low serum albumin as potential confounders in the association between l… (Journal of clinical lipidology 2026)
"While cholesterol-lowering trials have consistently demonstrated cardiovascular disease (CVD) benefits, some observational studies showed an elevated mortality risk from all-cause, CVD, and cancer in those with low total cholesterol (TC)." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Review of the epidemiological evidence for a possible relationship between hypocholesterol… (Cancer research 1983) · cited 57x in the literature
"the available data do not substantiate any direct cause and effect relationship between low blood cholesterol levels and cancer. Rather, the data suggest that low cholesterol levels may serve as a "marker," possibly genetic, and in only small numbers of male individuals in any given population" (abstract, conclusions, passage verified)
pubmed
Statins induce endothelial nitric oxide synthase expression, dilating blood vessels and reducing vascular inflammation.
"So they, for example, they induce nitric oxide synthase, which dilates your blood vessels and reduces inflammation and helps your lining of your blood vessels." (said at 0:56:40)
Extensive pharmacological and vascular research demonstrates that statins upregulate and activate endothelial nitric oxide synthase (eNOS). This occurs via cholesterol-independent (pleiotropic) mechanisms, primarily through the inhibition of isoprenoid synthesis and Rho/ROCK signaling, as well as activation of the PI3K/Akt pathway. The resulting increase in endothelial nitric oxide bioavailability promotes vasodilation, reduces vascular inflammation, and improves overall endothelial function.
Sex steroid hormones, including testosterone, are biochemically synthesized from cholesterol.
"sex hormones, which is what your testosterone is made from, is cholesterol." (said at 0:32:20)
The host's statement that sex steroid hormones, including testosterone, are biochemically synthesized from cholesterol is fully supported by established biochemical literature. Cholesterol serves as the initial precursor for all steroid hormones (including testosterone, progesterone, estrogens, cortisol, and aldosterone). The enzymatic pathway begins with the transport of cholesterol into mitochondria (facilitated by the steroidogenic acute regulatory [StAR] protein) and its cleavage into pregnenolone by the enzyme CYP11A1, which is subsequently converted through enzymatic steps into testosterone and other sex steroids.
The Framingham Heart Study began longitudinal data collection in Massachusetts in 1948.
"So these are the Framingham studies that, uh, you know, started in Massachusetts in 1948 and went over decades looking at thousands of people" (said at 0:46:54)
The statement is accurate. The Framingham Heart Study is the longest-running cardiovascular epidemiological cohort study; it was established in 1948 in Framingham, Massachusetts, collecting longitudinal data over multiple generations across several decades.
A 2016 systematic review of observational cohort studies found no association between LDL cholesterol levels and cardiovascular disease in individuals aged 60 and older.
"So we looked at: was there first of all any association if you're over 60 with LDL cholesterol and heart disease? We found none." (said at 0:55:08)
A 2016 systematic review by Ravnskov and colleagues evaluated 19 cohort studies (30 cohorts, 68,094 individuals aged 60 and older) examining LDL cholesterol and mortality outcomes. Regarding cardiovascular mortality across 9 cohorts where it was assessed, seven cohorts found no association with LDL-C levels, and two cohorts found cardiovascular mortality was highest in the lowest LDL-C quartile. For all-cause mortality, an inverse association or lack of association was observed. Because this evidence is derived entirely from observational cohort studies prone to reverse causation and residual confounding, the certainty of evidence is low.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.